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Objective: To characterize two Achromobacter xylosoxidans recovered from 2 patients
diagnosed with pertussis during a Bordetella pertussis surveillance program.
Methods: Nasopharyngeal swabs from 2 children under 1 year of age with clinical
suspicion of pertussis were analyzed by culture and PCR.
Results: Two Achromobacter xylosoxidans A8, closely related to Bordetella spp. were
recovered from 2 patients diagnosed of pertussis, both carrying the ptxA gene and IS418
the pertussis toxin encoding gene. Subsequently, antibiotic susceptibility was evaluated
by disk-diffusion method and by PCR.
Conclusions: Although more detailed studies are needed, the present data highlight the
possibility that Achromobacter xylosoxidans, closely related Bordetella pertusssis mi-
croorganisms and not covered under the vaccine umbrella, might also result in cases of
whooping cough. Thereby further surveillance is necessary to determine the extension
and relevance of their pathogenic role in order to discriminate their real public health
implication.1. Introduction
Respiratory tract infections are the leading cause of mortality
among children under ﬁve years of age worldwide, causing
around 1.5 millions of deaths yearly, especially in low and
middle income countries (LMC) [1]. Among these infections,
whooping cough (pertussis) is particularly severe, with theWHO reporting more than 16 million cases of pertussis and
around 195 000 deaths worldwide in 2008, 95% of which
were in LMC [1]. Pertussis is caused by Bordetella pertussis
(B. pertussis). It is potentially preventable by vaccination and
is characterized by a series of early symptoms which may be
easily misdiagnosed as a common cold, followed by a series
of paroxysmal symptoms at 1 or 2 weeks of evolution, which
may include coughing, whooping sounds, vomiting among
others that might result in death [2].
The introduction of the pertussis vaccination resulted in a
decrease in disease burden, but since the 80–90's of the last
century, the number of cases has risen again [3,4]. This re-
emergence of pertussis may be related to different causes,
including less effectivity of the current acellular pertussis vac-
cine with respect to the whole cell vaccine [4,5], the selection of
variants of B. pertussis not covered by the vaccine [5,6], as well
as the underestimated role of other Bordetella species, as such as
Bordetella holmesii [7]. Following these trends, in the last years
an increasing number of cases, mainly in rural areas, has been
described in Peru [8].ess article under the CC BY-NC-ND
Table 1
Clinical presentation of patients.
Symptoms Patient 1 Patient 2
Paroxysm of coughing – +
Respiratory distress + +
Wheezing – –
ABOS – –
Lung collapse – –
Apnea – –
Pneumonia + –
Post-cough vomiting + –
Cyanosis – +
Flush + +
Fever + +
Convulsion – –
Feeding difﬁculties + +
Diarrhea + –
Vaccination statusa 0 1
a Number of doses; ABOS: Acute bronchial obstructive syndrome.
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being detected in different sources, including water environ-
ments or different human microbiotas [9,10]. Achromobacter is a
genus closely related to Bordetella and it has been proposed to
have a potential virulence from an evolutionary point of view
[11]. In this line Achromobacter xylosoxidans (A. xylosoxidans)
has been described as a cause of different infections, mainly
bacteremia in immunosuppressed patients, but has also been
related to respiratory diseases, including infections in patients
with cystic ﬁbrosis, bronchiectasis and pleural emphysema,
among others [10,12–15]. However, to our knowledge it has
never been reported as a causal agent of pertussis-like illness.
The aim of this study was to characterize 2 A. xylosoxidans
isolated from pediatric patients diagnosed with whooping cough.
2. Materials and methods
2.1. Samples and clinical data
Nasopharyngeal swabs from 2 children under 1 year of age
with clinical suspicion of pertussis were collected during a
surveillance of pertussis and sent to the Instituto de Inves-
tigacio´n Nutricional/Universidad Peruana de Ciencias Aplica-
das. Relevant clinical data were recorded in a questionnaire. The
study was approved by the Ethical Committee of the Hospital
Nacional de Salud del Niño, Lima (Peru). The samples were
collected after the parents had provided signed informed
consent.
Clinical and epidemiological features were registered for
each patient, including: age, clinical symptoms (paroxysm of
coughing, cyanosis, respiratory distress, difﬁculty feeding, fever,
ﬂush, diarrhea, vomiting, wheezing, runny nose and expectora-
tion), days from the onset of symptoms and time elapsed until
the sample was collected and sent to the laboratory.
2.2. Clinical diagnosis
A direct nucleic acid extraction was performed from the
nasopharyngeal samples using the High Pure Template Prepa-
ration Kit (Roche Applied Science, Mannheim, Germany)
following the manufacturer's instructions, and pertussis status
was conﬁrmed by PCR. Thus, both 191 bp of the ptxA gene and
145 bp of the IS418 were ampliﬁed using primers described
elsewhere [16,17]. To conﬁrm the correctness of the
ampliﬁcations the PCR products were recovered, puriﬁed
(SpinPrepTM Gel DNA Kit, San Diego, USA) and sequenced
(Macrogen, Seoul, Korea). Additionally, the presence of
adenovirus, inﬂuenza A, B and C, syncytial respiratory virus
A and B, parainﬂuenza 1, 2, 3, 4a, enterovirus, rhinovirus and
coronavirus was veriﬁed as described elsewhere [18].
2.3. Bacterial culture and identiﬁcation
The nasopharyngeal samples were cultured in Bordet-
Gengou agar, incubated at 35 C in a moist atmosphere and
maintained for 5–7 days under aerobic conditions. Colonies
were identiﬁed based on characteristic morphology, Gram stain
appearance and catalase, oxidase testing. Positive cultures were
conﬁrmed by PCR of the ptxA gene as mentioned previously.
Additionally, a DNA fragment of 663 bp, including the ﬁrst
517 bp of the parC gene, was also ampliﬁed using the primers(50-GTGATCATTCCCAAGCGCC-30 and 50-TGAGCAGCAT-
CACGGGCA-30) and the conditions previously described by
Ohtsuka et al [19]. These primers are able to amplify the parC
gene from both Bordetella spp and A. xylosoxidans, which
may be easily differentiated by the presence of several
additional nucleotides in the N-terminal region of the parC
gene of A. xylosoxidans sequence.
2.4. Antibiotic susceptibility
The susceptibility levels to amoxicillin, azithromycin,
chloramphenicol, cotrimoxazole, erythromycin, clarithromycin,
cefotaxime, ampicillin, moxiﬂoxacin and tetracycline were per-
formed by disk diffusion.
2.5. Macrolide target study
The 23S rRNA gene was ampliﬁed from bacterial DNA ex-
tractions using the primers and conditions described previously
[20]. Additionally, the rplV and rplD genes from both
nasopharyngeal swabs and bacterial origins were ampliﬁed
using Bordetella-speciﬁc primers: rplV-F: 50-CGGACA
AGAAGTCGAAGAGG-30, rplV-R: 50-GTGACCGCGAGAC
GGAACCC-30 and rplD-F: 50-ATGGATCTCA
AGCTCCTGAATG-30, rplD-R: 50- TCATCCCAG
CATCTCCTCG-30 respectively. For both cases, the ﬁnal
volume of the PCR mixture was 50 mL, distributed as follows:
25 mL of enzyme mix (Taq polymerase, 2.5 mM MgCl2,
15 mM Tris/HCl pH 8.3, 50 Mm KCl, 200 mM of each
deoxynucleotide), 20 pmol of each primer (Macrogen, Seoul,
Korea), and 5 mL of DNA extraction. Thus, the PCR
conditions were: 95 C for 5 min, followed by 55 cycles of
95 C for 1 min, 55 C for 1 min and 72 C for 1 min, with a
ﬁnal elongation of 10 min at 72 C. Ampliﬁed products (rplV:
408 bp; rplD: 619 bp) were gel recovered and sequenced as
mentioned above.
3. Results
Both children presented fever, respiratory distress and
ﬂushed, while only one presented cough paroxysm (Table 1).
One of the children was treated with amoxicillin plus cephalexin
Table 2
Antibiotic susceptibility (mm).
Antibiotic Patient 1 Patient 2
Ampicillin 0 0
Amoxicillin 0 0
Cefotaxime 0 0
Erythromycin 0 0
Azithromycin 0 0
Clarithromycin 0 0
Chloramphenicol 14 16
Cotrimoxazole 14 30
Moxiﬂoxacin 22 18
Tetracycline 16 16
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cases the treatment was successful and the children were dis-
charged from hospital.
In both cases the PCR of the direct DNA extraction from
nasopharyngeal swabs was positive for the presence of the ptxA
gene and IS418, which showed a 100% of identity with that of
B. pertussis (GenBank accession number NC_002929). Addi-
tionally, none of the other pathogens sought was detected, and
thus, the patients were diagnosed with pertussis.
The antibiotic susceptibility analysis showed that the isolates
present high levels of resistance to tested antibacterial agents,
including all analyzed macrolides (Table 2).
Surprisingly, when the macrolide target encoding genes were
ampliﬁed and sequenced, the results showed the presence of
A. xylosoxidans A8 with 100% (23S rRNA gene) 99% (rplD
gene) and 98% (rplV gene) of identity with the respective DNA
sequences of A. xylosoxidans A8 (GenBank access
CP002287.1), being even higher than the identity levels with the
same DNA sequences of B. pertussis (Genbank access
NC_002929) or other Bordetella spp. These results were also
conﬁrmed on PCR analysis of the grown microorganisms.
For further identiﬁcation tool, we included the analysis of the
parC gene sequence, which also showed that the closest related
sequence was that of A. xylosoxidans A8, being 2–6 amino acid
codons longer than other Achromobacter spp. and Bordetella
spp. ParC sequences present in GenBank. Thus, despite the
presence of 27 differences (96% of identity) in the encoding
ParC DNA sequence both samples, only showed 3 different
amino acid changes: S15P; D20G and Y66F.
Regarding the aforementioned macrolide targets no mutation
was found in the 23S rRNA gene and only 5 and 7 silent mu-
tations were found in the rplD genes on comparison with the
A. xylosoxidans A8 wild-type sequence, while 6 silent mutations
plus the T134A transversion resulting in the amino acid change
V45A was observed in both rplV genes.
4. Discussion
Achromobacter spp. are frequent environmental microor-
ganisms, causing a series of opportunistic illnesses, including
respiratory diseases [15,21] and possess a high evolutionary
virulence potential, because of their phylogenetical proximity
to Bordetella. In this line, the description of A. xylosoxidans
in pediatric whooping cough patients is strongly suggestive of
its implication as an etiological agent, especially as the isolate
analysis showed the presence of the ptxA gene as well as
IS418. A DNA fragment including the N-terminal of parC
gene was also ampliﬁed to conﬁrm these data. This gene wasselected because the N-terminal section in A. xylosoxidans A8
has 5 to 6 more amino acid than the described ParC of
Bordetella spp. Moreover, this sequence is also 2 to 5 amino
acids longer than ParC of other Achromobacter.
The presence of non-B. pertussis microorganisms causing
whooping cough has a direct implication in the lack or dimin-
ishing protection of vaccines and having a direct public health
impact. Nonetheless, in this case only one child was partially
vaccinated since the ﬁrst vaccine dosage is provided at 2 months
of life.
While IS418 is present with a variable copy number in
different Bordetella genus members, the so-called pertussis toxin
is exclusively produced by B. pertussis [22]. However, different
members of the genus Bordetella, such as Bordetella
bronchiseptica and Bordetella parapertussis, which have been
involved as etiological causes of this illness, possess closely
related non-functional genes [22]. Other Bordetella genus
members, such as B. holmesii, which account for 0.4%–29%
of all diagnosed pertussis cases [23,24], do not present the
either pertussis toxin gene or close-related genes, a character-
istic which has been used in different studies to facilitate the
differentiation between B. pertussis and B. holmesii [25]. Thus,
pertussis toxin functionality, although relevant, is not essential
for the presence of pertussis-like symptoms. In our case no
data about gene functionality was obtained, remaining to be
established (studies ongoing).
The antimicrobial susceptibility analysis, showed high levels
of resistance to macrolides. This is a matter of concern, since
macrolides are considered as the treatment of choice for
pertussis [26], and again highlight the need to correctly determine
the etiologic agent, causing the illness. Along this line, it has
been reported that different Bordetella species present different
levels of macrolide resistance, which is especially high in
B. holmesii [7].
Regarding macrolide targets, the only amino acid codon
alteration with respect to A. xylosoxidans A8 wild-type se-
quences was observed in the rplV gene. Thus, the V45A amino
acid codon substitution was observed in the protein L22 in both
isolates. However, to the best of our knowledge, substitutions at
this amino acid codon, or at equivalent positions in other mi-
croorganisms, have not been related to macrolide resistance.
Nonetheless, the presence of this speciﬁc amino acid change
may be a polymorphism without involvement in the develop-
ment of macrolide resistance. Obviously, the presence of
transferable mechanisms of macrolide resistance can not be
ruled out. Thus, a GenBank search has showed the presence of
the ere(A) gene in other members of the Achromobacter genus
(GenBank access: DQ112222.1).
Interestingly, some silent DNA mutations were found in both
strains in the rplV, rplD and parC genes. These close similarities
between the two isolates, together with the short isolation frame
time between the two isolates suggest the presence of a speciﬁc
A. xylosoxidans A8 clone or a close related microorganism, with
the ability to cause pertussis-like illness in the area. Taking this
into account the recent report by Spilker et al [27] is of special
interest. These authors reported the presence of several new
putative Bordetella-like species, suggesting the presence of an
undescribed genus closely related to both A. xylosoxidans and
Bordetella spp.
In summary, the present results show the presence of
A. xylosoxidans A8-like microorganism possessing the ptxA
gene and IS418. Due the proximity of the Achromobacter
Fiorella Orellana-Peralta et al./Asian Paciﬁc Journal of Tropical Medicine 2015; 8(6): 464–467 467genome to that of Bordetella spp. causing whooping cough, in
depth characterization of the isolates recovered is need. The
present data highlight the possibility that closely related
B. pertusssis microorganisms, not covered under the vaccine
umbrella, might also result in cases of whooping cough, thereby
requiring further surveillance to determine the extension and
relevance of their pathogenic role in order to discriminate their
real public health implication.
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